Yokoyama Kazuhiro, Ishikawa Noriko, Igarashi Susumu, Kawano Noriyuki, Masuda Naoyuki, Hattori Kazuyuki, Miyazaki Takahiro, Ogino Shin-ichi, Orita Masaya, Matsumoto Yuzo, Takeuchi Makoto, Ohta Mitsuaki
Drug Discovery Research, Astellas Pharma Inc., 21 Miyukigaoka, Tsukuba-shi, Ibaraki 305-8585, Japan.
Bioorg Med Chem. 2008 Sep 1;16(17):7968-74. doi: 10.1016/j.bmc.2008.07.062. Epub 2008 Jul 29.
A series of CC chemokine receptor-4 (CCR4) antagonists were examined in a previous report in an attempt to improve metabolic stability in human liver microsomes. In this study, the cycloheptylamine moiety of N-cycloheptyl-6,7-dimethoxy-2-(4-pyrrolidin-1-ylpiperidin-1-yl)quinazolin-4-amine 1 was replaced with the p-chloroaniline moiety, and the resulting compound, N-(4-chlorophenyl)-6,7-dimethoxy-2-(4-pyrrolidin-1-ylpiperidin-1-yl)quinazolin-4-amine (8c), retained its potency ([(35)S]GTPgammaS-binding inhibition and CCL22-induced chemotaxis in humans/mice). Based on the structure-activity relationships (SAR), a homology model was constructed for CCR4 to explain the binding mode of 8c. Overall, there was good agreement between the docking pose of the CCR4 homology model and the human [(35)S]GTPgammaS assay results. Administration of 8c in a murine model of acute dermatitis showed anti-inflammatory activity (oxazolone-induced contact hypersensitivity test).
在之前的一份报告中对一系列C-C趋化因子受体4(CCR4)拮抗剂进行了研究,以试图提高其在人肝微粒体中的代谢稳定性。在本研究中,N-环庚基-6,7-二甲氧基-2-(4-吡咯烷-1-基哌啶-1-基)喹唑啉-4-胺1的环庚胺部分被对氯苯胺部分取代,所得化合物N-(4-氯苯基)-6,7-二甲氧基-2-(4-吡咯烷-1-基哌啶-1-基)喹唑啉-4-胺(8c)保留了其活性(对人/小鼠的[(35)S]GTPγS结合抑制和CCL22诱导的趋化作用)。基于构效关系(SAR),构建了CCR4的同源模型以解释8c的结合模式。总体而言,CCR4同源模型的对接姿势与人[(35)S]GTPγS测定结果之间有良好的一致性。在急性皮炎小鼠模型中给予8c显示出抗炎活性(恶唑酮诱导的接触性超敏反应试验)。